CompletedNot Applicable

Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring

Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo13,747 participantsStarted 2019-09-01

Plain-language summary

This study determines the feasibility, diagnostic performance and cost for monitoring of eliminated human African trypanosomiasis (HAT) foci using diagnostic algorithms of serological and molecular high throughput tests with and without previous rapid diagnostic test blood screening for early detection of Trypanosoma brucei gambiense HAT re-emergence.

Who can participate

Age range4 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Permanent resident of village (in low to zero prevalence HAT focus) for minimum 1 year Exclusion Criteria: * Previously treated for HAT (irrespective of time elapsed since treatment) * No informed consent * \< 4 years old

What they're measuring

Sensitivity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on the population at risk

Timeframe: 6 months

Specificity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on the population at risk

Timeframe: 6 months

Trial details

NCT IDNCT04099628

SponsorInstitut de Recherche pour le Developpement

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2021-01-31

View on ClinicalTrials.gov More Human African Trypanosomiasis trials